SURGEPAYS INC (SURG) Stock Fundamental Analysis
USA - NASDAQ:SURG - US86882L2043 - Common Stock
2.71 USD
+0.01 (+0.37%)
SURG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 22 industry peers in the Wireless Telecommunication Services industry. SURG has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SURG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SURG had negative earnings in the past year.
SURG had a negative operating cash flow in the past year.
In the past 5 years SURG reported 4 times negative net income.
In multiple years SURG reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -320.77%, SURG is not doing good in the industry: 95.45% of the companies in the same industry are doing better.
SURG has a worse Return On Equity (-42037.73%) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -320.77% | ||
| ROE | -42037.73% | ||
| ROIC | N/A |
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SURG has more shares outstanding
The number of shares outstanding for SURG has been increased compared to 5 years ago.
SURG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -12.50, we must say that SURG is in the distress zone and has some risk of bankruptcy.
SURG's Altman-Z score of -12.50 is on the low side compared to the rest of the industry. SURG is outperformed by 95.45% of its industry peers.
SURG has a Debt/Equity ratio of 53.87. This is a high value indicating a heavy dependency on external financing.
SURG has a Debt to Equity ratio of 53.87. This is amonst the worse of the industry: SURG underperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 53.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.5 |
ROIC/WACCN/A
WACC8.71%
2.3 Liquidity
SURG has a Current Ratio of 1.11. This is a normal value and indicates that SURG is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.11, SURG perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 0.84 indicates that SURG may have some problems paying its short term obligations.
SURG has a worse Quick ratio (0.84) than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2855.56%.
The Revenue for SURG has decreased by -67.73% in the past year. This is quite bad
SURG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.83% yearly.
EPS 1Y (TTM)-2855.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.97%
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-23.65%
3.2 Future
The Earnings Per Share is expected to grow by 44.47% on average over the next years. This is a very strong growth
SURG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.43% yearly.
EPS Next Y65.13%
EPS Next 2Y44.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20.56%
Revenue Next 2Y63.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SURG. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 13.28, the valuation of SURG can be described as correct.
SURG's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of SURG to the average of the S&P500 Index (33.61), we can say SURG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.28 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SURG's earnings are expected to grow with 44.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
SURG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SURG (11/11/2025, 12:14:58 PM)
2.71
+0.01 (+0.37%)
Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)
Earnings (Next)
Inst Owners8.12%
Inst Owner Change3.58%
Ins Owners36.83%
Ins Owner Change1.25%
Market Cap55.37M
Revenue(TTM)36.46M
Net Income(TTM)-48.81M
Analysts80
Price Target9.69 (257.56%)
Short Float %1.27%
Short Ratio1.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.1%
Min EPS beat(2)-75.97%
Max EPS beat(2)-60.24%
EPS beat(4)0
Avg EPS beat(4)-152.16%
Min EPS beat(4)-304.04%
Max EPS beat(4)-60.24%
EPS beat(8)1
Avg EPS beat(8)-184.11%
EPS beat(12)4
Avg EPS beat(12)-2.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.44%
Min Revenue beat(2)-30.02%
Max Revenue beat(2)-14.86%
Revenue beat(4)1
Avg Revenue beat(4)-19.09%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-11.04%
Revenue beat(12)3
Avg Revenue beat(12)-9.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.56%
PT rev (3m)5.56%
EPS NQ rev (1m)34.09%
EPS NQ rev (3m)-52.63%
EPS NY rev (1m)3.61%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)-26.85%
Revenue NQ rev (3m)-30.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.28 | ||
| P/S | 1.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 476.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.48
EYN/A
EPS(NY)0.2
Fwd EY7.53%
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS1.78
BVpS0.01
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -320.77% | ||
| ROE | -42037.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 53.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | -12.5 |
F-Score2
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2855.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.97%
EPS Next Y65.13%
EPS Next 2Y44.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-23.65%
Revenue Next Year20.56%
Revenue Next 2Y63.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3934%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-937.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-924.59%
OCF growth 3YN/A
OCF growth 5YN/A
SURGEPAYS INC / SURG FAQ
Can you provide the ChartMill fundamental rating for SURGEPAYS INC?
ChartMill assigns a fundamental rating of 2 / 10 to SURG.
What is the valuation status of SURGEPAYS INC (SURG) stock?
ChartMill assigns a valuation rating of 4 / 10 to SURGEPAYS INC (SURG). This can be considered as Fairly Valued.
What is the profitability of SURG stock?
SURGEPAYS INC (SURG) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for SURG stock?
The Earnings per Share (EPS) of SURGEPAYS INC (SURG) is expected to grow by 65.13% in the next year.